Shaheer A Khan
Shaheer A Khan
Kunle Odunsi
Kunle Odunsi
Ghayas C Issa
Ghayas C Issa
Multikinase inhibitors in refractory metastatic colorectal cancer: an optimal sequence? [0.03%]
refractory转移性结肠癌的多激酶抑制剂：最佳顺序吗？
Celine Hoyek,Angelo Pirozzi,Naohiro Okano et al.
Celine Hoyek et al.
Despite major advances in management strategies, metastatic colorectal cancer remains an important clinical challenge because most patients experience progression after standard first- and secondline treatments. In the setting of refractory...
The clinical applications of next-generation sequencing and ctDNA/cfDNA in lymphoma [0.03%]
下一代测序和ctDNA/cfDNA在淋巴瘤中的临床应用
Andrew Ip,Lindsay M Fogel,Bianca DeAgresta et al.
Andrew Ip et al.
Next-generation sequencing (NGS) technology plays a pivotal role in understanding the molecular landscape in oncology by providing a comprehensive analysis of genomic mutations. The detection and analysis of mutations have improved through ...
Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations [0.03%]
FRESCO临床研究证据应用于实践：一例无靶向突变的晚期结直肠癌患者使用呋喹替尼三线治疗后接受曲氟尿苷/替吡拉西四线治疗的案例报告
Tiago Biachi,Jessica Shostak
Tiago Biachi